GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hoth Therapeutics Inc (NAS:HOTH) » Definitions » PB Ratio

Hoth Therapeutics (Hoth Therapeutics) PB Ratio : 0.58 (As of May. 12, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Hoth Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-12), Hoth Therapeutics's share price is $1.1702. Hoth Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $2.03. Hence, Hoth Therapeutics's PB Ratio of today is 0.58.

The historical rank and industry rank for Hoth Therapeutics's PB Ratio or its related term are showing as below:

HOTH' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 4.71
Current: 0.58

During the past 7 years, Hoth Therapeutics's highest PB Ratio was 4.71. The lowest was 0.00. And the median was 0.00.

HOTH's PB Ratio is ranked better than
90.24% of 1311 companies
in the Biotechnology industry
Industry Median: 2.5 vs HOTH: 0.58

During the past 12 months, Hoth Therapeutics's average Book Value Per Share Growth Rate was -48.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -38.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 21.90% per year.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Hoth Therapeutics was 192.70% per year. The lowest was -38.30% per year. And the median was -12.70% per year.

Back to Basics: PB Ratio


Hoth Therapeutics PB Ratio Historical Data

The historical data trend for Hoth Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hoth Therapeutics PB Ratio Chart

Hoth Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial 26.14 6.86 1.60 1.98 0.71

Hoth Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.98 0.57 1.00 0.63 0.71

Competitive Comparison of Hoth Therapeutics's PB Ratio

For the Biotechnology subindustry, Hoth Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hoth Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hoth Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Hoth Therapeutics's PB Ratio falls into.



Hoth Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Hoth Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=1.1702/2.027
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Hoth Therapeutics  (NAS:HOTH) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Hoth Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Hoth Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hoth Therapeutics (Hoth Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
1 Rockefeller Plaza, Suite 1039, New York, NY, USA, 10020
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Executives
Jeff Pavell director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Robb Knie director, officer: CEO and President C/O INVENTERGY GLOBAL, INC., 900 EAST HAMILTON AVENUE SUITE 180, CAMPBELL CA 95008
Stefanie Johns officer: Chief Scientific Officer 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Anthony Hayes director 1796 SHADY LANE, COLUMBIA SC 29206
Wayne Linsley director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Graig Springer director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Spherix Inc 10 percent owner 725 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Vadim Mats director 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Rice Kenneth L Jr director C/O 85 MAIN STREET, HOPKINTON MA 01748
David Sarnoff director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
David S. Briones officer: Chief Financial Officer C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Matthew D. Eitner 10 percent owner 44 BRAMS HILL DRIVE, MAHWAH NJ 07430
Kevin Jess Poor 10 percent owner 750 BEULAHS LANE, IDAHO FALLS ID 83401
James P. Ahern 10 percent owner 20 WEST 64TH STREET, APT 18RS, NEW YORK NY 10023

Hoth Therapeutics (Hoth Therapeutics) Headlines